BioCryst Pharmaceuticals | BCRX - Interest Expense On Debt


BioCryst Pharmaceuticals reported $21.71M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Chugai Pharma JPY 95M 260M Dec/2025
Daiichi Sankyo JPY 14.13B 10.56B Sep/2026
DBV Technologies USD 461K 323.71K Mar/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
Incyte USD 605K 23K Sep/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026